BridgeMD
Men4age study
EU CTIS ID: 2024-513640-29-00
What this study is testing
Functional antibody levels against MenA, MenC, MenW and MenY are measured using the serum bactericidal antibody (SBA) assay.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants eligible for this study are Dutch older persons 65-85 years of age
- Moderate to good general health with regard to age
- Did not receive a MenACWY-TT vaccine before
You likely can't join if
- Antibiotic use within 14 days of enrolment
- Serious surgery within the last 3 months
- Previous vaccination with the MenC, MenC-TT or MenACWY-TT vaccine
- Previous confirmed or suspected meningococcal disease
- Any vaccination within a month before enrolment
- Known or suspected allergy to any of the vaccine components (by medical history)
See the full eligibility criteria
- Participants eligible for this study are Dutch older persons 65-85 years of age
- Moderate to good general health with regard to age
- Did not receive a MenACWY-TT vaccine before
- Antibiotic use within 14 days of enrolment
- Serious surgery within the last 3 months
- Previous vaccination with the MenC, MenC-TT or MenACWY-TT vaccine
- Previous confirmed or suspected meningococcal disease
- Any vaccination within a month before enrolment
- Known or suspected allergy to any of the vaccine components (by medical history)
- Severe acute infectious illness or fever above 38.0 °C within 14 days before vaccination
- Present evidence of serious diseases either demanding regular use of oral immunosuppressive medical treatment, like corticosteroids, that might interfere with the results of the study within the last 3 months or demanding acute use of high dose oral immunosuppressive that might interfere with the results of the study within the last 2 weeks
- Occurrence of a serious adverse event after other vaccination by medical history
- Known or suspected immune deficiency
- Known or suspected coagulation disorder
- Oral hormone use, such as postmenopausal hormones, within the last 3 months
- History of one of the following neurological disorders: multiple sclerosis, Parkinson’s disease, or epilepsy
- Previous administration of plasma-serum products including immunoglobulins within 6 months before vaccination and blood sampling
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.